Investor Relations

Upcoming Event

Annual Meeting of Stockholders

Latest Event

January 25, 2023
PPMD Webinar

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Company Overview

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor’s current focus is on developing exosomes capable of delivering nucleic acids as well as proteins to treat or prevent a variety of diseases.

Investor Relations

Capricor Therapeutics, Inc.

IR Contacts

Corporate & Research Headquarters

Capricor Therapeutics, Inc.
10865 Road to the Cure
Suite 150
San Diego, CA 92121
United States
T: 858-727-1755

Transfer Agent

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
United States

Investor Relations

LifeSci Advisors, LLC
Joyce Allaire
T: 617-435-6602